R1 RCM sells 340B referral capture business to NuvemRx

PHILADELPHIA and MASSACHUSETTS, UNITED STATES — R1 RCM’s 340B referral capture business, formerly known as par8o, has been acquired by NuvemRx. 

This acquisition allows R1 RCM to sharpen its core focus while ensuring its specialized referral technology continues to thrive under NuvemRx’s expanding tech-enabled pharmacy platform.

340B referral capture enables safety-net providers to stretch scarce resources by purchasing outpatient medications at significantly reduced prices, a financial advantage strategically extended through mechanisms like referral capture to reinvest in patient care for vulnerable populations.

The transition significantly bolsters NuvemRx’s national footprint, equipping community health providers with enhanced tools to capture prescription savings and improve patient retention.

“With NuvemRx, we now have a complete solution that brings together TPA, pharmacy management, and referral capture services under a single, mission-aligned partner,” said Melissa Opraseuth, Chief Operating Officer (COO) of par8o, who will also join the NuvemRx team.

Consolidating the 340B healthcare technology landscape

NuvemRx, which provides a suite of scalable solutions that integrate software, intelligence, and expert support to simplify pharmacy operations for community health providers, has effectively acquired a key competitor and technology integrator and has treated over 25 million patients. 

par8o, known for its innovative specialty in 340B referral capture and expansive integrations with major national pharmacy partners, brings a complementary and critical capability to NuvemRx’s existing portfolio. This move directly follows Par8o’s acquisition by R1 RCM as part of the Cloudmed transaction in 2022.

By integrating Par8o’s advanced technology and deep pharmacy integrations, NuvemRx is creating a more comprehensive, one-stop platform for covered entities, which are hospitals and clinics serving vulnerable populations. 

The combined entity now supports more than 800 covered entities nationwide, representing a massive network serving over 70 million cumulative patients. 

The powerful combination of third-party administrator (TPA) services, pharmacy management, and now advanced referral services presents a unique opportunity for these entities to optimize their entire pharmacy care delivery model under a single provider, potentially increasing efficiency and market control.

Scott Seidelmann, Chief Executive Officer (CEO) of NuvemRx, notes, “By bringing par8o’s referral technology, enhanced with AI-powered decision support, into our suite of services, we can automate up to 85 percent of the referral and eligibility process.”

“This offers providers another opportunity to reduce the administrative burden associated with the 340B program and allows patients to receive high-quality integrated care.”

Real-time 340B referral visibility boosts patient savings 

Par8o’s core mission was to advance access to care by turning eligible outpatient referrals into compliant 340B savings at scale, a function that directly complements NuvemRx’s goal of helping providers deliver on their mission. 

The acquisition has the direct benefit of expanding NuvemRx’s capabilities, enabling covered entities to capture specialty referrals more effectively, retain their patients within their networks, and adapt to ongoing rebate and reimbursement changes, which immediately address some of the most frequent concerns in the 340B ecosystem.

The most significant technological integration is a crucial gap bridging with the provision of real-time visibility in the referral, which is a feature critical to the modern functioning of a pharmacy. 

Such visibility helps providers identify authoritative prescribing, achieve additional savings, and minimize leakage across specialty care processes where costly medications are frequently prescribed.

For community health providers, this implies combining strong services that can be directly translated into increased eligible prescription savings, which can be reinvested in patient care services.

Finally, the combined abilities will be targeted at taking patient care to the next level, with more prescriptions recorded in the safety-net system, enhancing continuity of care and the financial sustainability of the organizations that care for them.